A new study conducted by researchers at McMaster University suggests that certain bacteria in the human mouth and gut may play a significant role in breaking down proteins that trigger peanut allergies. Published in the journal Cell Host & Microbe, the research reveals that these beneficial microbes are already present in the body’s microbiome, particularly in the mouth and digestive tract.
The study highlights two peanut proteins, known as Ara h 1 and Ara h 2, which are commonly associated with allergic reactions. Among the tested bacteria, one species, Rothia aeria, demonstrated remarkable ability in laboratory experiments, nearly eliminating both allergen proteins. This finding raises promising possibilities for reducing the immune response that makes peanut allergies potentially life-threatening.
Peanut allergies affect approximately 2% of individuals in Western countries, often persisting into adulthood. Even minimal exposure can lead to symptoms that range from hives to severe anaphylaxis, a condition that can result in difficulty breathing and even death. The research team sought to understand the varying degrees of tolerance to peanut exposure, discovering that some individuals can manage minor exposures while others experience catastrophic reactions.
Saliva Samples Provide Insight into Tolerance
To explore this phenomenon, scientists collected saliva samples from volunteers without food allergies and assessed how well their oral bacteria could break down peanut proteins in controlled laboratory settings. Additionally, mouse models with peanut allergies were utilized to evaluate the impact of these bacteria on immune responses.
The findings indicate that individuals with a higher tolerance to peanut exposure tend to have greater quantities of Rothia aeria in their saliva. This suggests that the presence of this particular microbe may correlate with an increased ability to handle peanut allergens without adverse effects.
The implications of this research could pave the way for innovative therapeutic approaches. By potentially introducing beneficial microbes like Rothia aeria into the human body, researchers aim to complement existing treatments, such as oral immunotherapy. This method involves gradual exposure to small amounts of allergens, helping patients build immunity over time.
As the study unfolds, it raises intriguing questions about the future of peanut allergy management. If further research supports these findings, it could lead to new probiotic treatments specifically designed to harness the power of beneficial bacteria in combating food allergies.
